-
Clin Cancer Res: The impact of different treatments and gene mutations on the prognosis of patients with intrahepatic cholangiocarcinoma
Time of Update: 2021-05-20
For IHC patients with positive lymph node metastasis, there is no difference in survival between surgical resection and hepatic artery infusion chemotherapy, but both are better than system chemotherapy alone.
-
SpaceX starship SN15 landed smoothly than expected, Cao Yuan's graphene research made a new breakthrough | Science and Technology Guide
Time of Update: 2021-05-20
Ultra-fast non-volatile memory with 20 ns write/eraseUltra-fast non-volatile memory with 20 ns write/eraseOn May 3, in a study on Nature Nanotechnology, researchers constructed ultra-fast, non-volatile floating gate memory devices that achieved nanosecond (~20 ns) read and write Time, extremely high erase/write ratio (~1010) and storage time of more than 10 years.
-
Am J Clin Nutr: Correlation between dairy products and calcium intake and breast cancer risk
Time of Update: 2021-05-20
1093/ajcn/nqab097" target="_blank" rel="noopener">Dairy foods, calcium, and risk of breast cancer overall and for subtypes defined by estrogen receptor status: a pooled analysis of 21 cohort studies .
-
Eur J Nucl Med Mol Imaging: Using PERCIST to predict tumor response and prognosis of patients with esophageal squamous cell carcinoma to neoadjuvant chemotherapy
Time of Update: 2021-05-20
1007/s00259-021-05365-5">Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan .
1007/s00259-021-05365-5">Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan in this message
-
Nat Med: Phase I trial and biomarker analysis of Belzutifan's inhibition of renal cell carcinoma
Time of Update: 2021-05-20
Therefore, this study shows that Belzutifan is well tolerated and exhibits preliminary anti-tumor activity in a large number of pretreated patients , indicating that HIF-2α inhibition may provide an effective treatment for ccRCC.
-
2020 Oncology New Drug Data Card-Ensatinib
Time of Update: 2021-05-20
The interim analysis results of the international multicenter head-to-head, first-line phase III eXalt3 trial published at the World Conference on Lung Cancer (WCLC) Forum in August 2020 showed that in the ITT population, compared with crizotinib, enzatinib is the first-line treatment The median PFS of ALK-positive NSCLC was significantly longer (25.
-
Lancet Oncol: Efficacy and safety of trastuzumab drutecan for HER2-positive metastatic colorectal cancer
Time of Update: 2021-05-20
1016/S1470-2045(21)00086-3" target="_blank" rel="noopener">Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial .
1016/S1470-2045(21)00086-3" target="_blank" rel="noopener">Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial in this message
-
Oncologist: The efficacy and safety of cimiprizumab+radiotherapy+cyclophosphamide+GM-CSF in the treatment of recurrent/metastatic head and neck squamous cell carcinoma
Time of Update: 2021-05-20
Cimiprizumab combined with radiotherapy, cyclophosphamide and granulocyte macrophage colony stimulating factor (GM-CSF) is not as effective as other PD-1 inhibitors in patients with refractory/metastatic head and neck squamous cell carcinoma Monotherapy.
-
Hepatology International: Lenvatinib + TACE vs. TACE in Unresectable Liver Cancer: A Retrospective Controlled Study
Time of Update: 2021-05-20
In terms of disease-free survival, the 1-year and 2-year PFS rates of the lenvatinib+TACE group were 78.
Adverse eventsIn summary, lenvatinib+TACE significantly improved the clinical prognosis of unresectable liver cancer compared with TACE alone.
-
Nat Commun: Protein Analysis of Cellular Exosomes (EVs): Potential Monitoring Indicators for Treatment Response of Patients with Metastatic Breast Cancer
Time of Update: 2021-05-20
1038/s41467-021-22913-7">Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer .
1038/s41467-021-22913-7">Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer Leave a message here
-
The guy suffers from stomach cancer after a hungry meal. The body has these distress signals before the onset of stomach cancer.
Time of Update: 2021-05-20
According to Jiangsu News, a 28-year-old young man in Huai'an recently sought medical treatment due to unbearable abdominal pain and was diagnosed with gastric cancer.
Repeated dull pain in the abdomenSimilar to gastritis and gastric ulcers, most gastric cancers will have symptoms such as stomach pain in the early stages.
-
Nat Commun: BCMA/CS1 bispecific CAR can prevent antigen escape during CAR-T treatment of MM
Time of Update: 2021-05-20
gov/32385241/" target="_blank" rel="noopener">Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma .
gov/32385241/" target="_blank" rel="noopener">Systematically optimized BCMA / CS1 bispecific CAR- T cells robustly control heterogeneous multiple myeloma in this message
-
J Immunother Cancer: Radiotherapy combined with anti-PD-1 therapy before surgery can improve the pathological remission rate of advanced head and neck cancer
Time of Update: 2021-05-20
1136/jitc-2021-002485">Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma .
-
Cell Death Differ: Intestinal microflora affects the clinical outcome and treatment side effects of early breast cancer
Time of Update: 2021-05-20
1038/s41418-021-00784-1">Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment .
1038/s41418-021-00784-1">Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment Leave a message here
-
Ann Surg: Neoadjuvant radiotherapy VS. Surgical treatment for stage II/III rectal cancer with or without high-risk factors
Time of Update: 2021-05-20
In summary, the results of the study indicate that stratifying stage II/III rectal cancer based on risk factors and making it a more precise sub-category may result in differences in survival rates and local recurrence control.
-
Leuk Lymphoma: CD19 CAR T therapy can be used to treat patients with recurrent Ph+ALL with T315I mutation
Time of Update: 2021-05-20
In summary, the results of this study confirmed the efficacy of anti-CD19 CAR T cell therapy in the treatment of recurrent Ph+ALL with T315I mutation before and after allo-HSCT, and the therapy can be used in combination with Pranatinib.
-
Lancet Haematol: Combined infusion of humanized anti-CD19 and anti-BCMA CAR T cells or a new therapy for the treatment of relapsed or refractory multiple myeloma
Time of Update: 2021-05-20
Researchers from the Affiliated Hospital of Xuzhou Medical University in China conducted a single-center, single-arm, phase 2 clinical trial to evaluate the combination of humanized anti-CD19 and anti-BCMA CAR T cells in relapsed or refractory multiple myeloma The results of the study on activity and safety in patients have been published in Lancet Haematol.
-
JCO: Efficacy and safety of Pembrolizumab combined with Ipilimumab in the treatment of melanoma with PD1/PDL1 inhibitor failure
Time of Update: 2021-05-20
Progression-free time and duration of clinical response 87% (62/70) of the patients had any degree of treatment-related adverse events , the common ones were skin itching, rash, diarrhea, fatigue, nausea, and elevated transaminases .
-
J Clin Oncol: Apalutamide combined with ADT can effectively improve the prognosis of metastatic castration-sensitive prostate cancer
Time of Update: 2021-05-20
In summary, the final results of the TITAN trial proved that even if there is a crossover between the intervention groups, apalutamide combined with ADT treatment can improve the OS of mCSPC patients, delay the onset of castration resistance, maintain health-related quality of life , and be safe Sex can be.
-
Lancet Oncology: Atezolizumab's global phase 3 clinical trial showed poor efficacy for advanced bladder cancer
Time of Update: 2021-05-20
406 patients in the experimental group received an intravenous injection of 1200 mg of atezolizumab every 3 weeks, and 403 patients in the control group remained under observation after surgery without additional treatment.
